2021ESMO-贝伐珠单抗联合奥希替尼和化疗治疗EGFR突变晚期非小细胞肺癌脑转移疗效优越，安全可控
2021ESMO会议上发布了《Effectiveness of osimertinib plus chemotherapy and avastin for EGFR-mutated advanced non-small cell lung cancer with brain metastases》这篇研究摘要，研究结果显示：贝伐珠单抗联合奥希替尼和化疗治疗EGFR突变晚期非小细胞肺癌（NSCLC）脑转移及并发脑水肿的患者疗效优越，安全可控。
背景
研究设计
图1 研究流程
疗效评估
安全性评估
编译：陈恒 审校：沈怡
参考文献
H. Qin, S. Wang, F. Gao, et al. Effectiveness of osimertinib plus chemotherapy and avastin for EGFR-mutated advanced non-small cell lung cancer with brain metastases. ESMO Congress 2021, Abstract 1216P.
https://oncologypro.esmo.org/meeting-resources/esmo-congress-2021/effectiveness-of-osimertinib-plus-chemotherapy-and-avastin-for-egfr-mutated-advanced-non-small-cell-lung-cancer-with-brain-metastases
*仅供医疗专业人士阅读